Hematologic toxicities associated with intravenous immunoglobulin therapy.

Allison Baxley, Mojtaba Akhtari

Research output: Contribution to journalArticle

Abstract

Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.

Original languageEnglish (US)
Pages (from-to)1663-1667
Number of pages5
JournalInternational Immunopharmacology
Volume11
Issue number11
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Therapeutics
Rheology
Disseminated Intravascular Coagulation
Hemolytic Anemia
Leukopenia
Neutropenia
Autoimmune Diseases
Antibody Formation
Infection

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Hematologic toxicities associated with intravenous immunoglobulin therapy. / Baxley, Allison; Akhtari, Mojtaba.

In: International Immunopharmacology, Vol. 11, No. 11, 11.2011, p. 1663-1667.

Research output: Contribution to journalArticle

Baxley, Allison ; Akhtari, Mojtaba. / Hematologic toxicities associated with intravenous immunoglobulin therapy. In: International Immunopharmacology. 2011 ; Vol. 11, No. 11. pp. 1663-1667.
@article{42a89a67c9754a089322a8162886f0ca,
title = "Hematologic toxicities associated with intravenous immunoglobulin therapy.",
abstract = "Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.",
author = "Allison Baxley and Mojtaba Akhtari",
year = "2011",
month = "11",
language = "English (US)",
volume = "11",
pages = "1663--1667",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Hematologic toxicities associated with intravenous immunoglobulin therapy.

AU - Baxley, Allison

AU - Akhtari, Mojtaba

PY - 2011/11

Y1 - 2011/11

N2 - Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.

AB - Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.

UR - http://www.scopus.com/inward/record.url?scp=84860233959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860233959&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1663

EP - 1667

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 11

ER -